<DOC>
	<DOCNO>NCT00763867</DOCNO>
	<brief_summary>Diastolic heart failure ( DHF ) , affect old individual woman disproportionate rate , condition lead shortness breath fluid build-up lung . This study evaluate effectiveness medication sildenafil improve exercise ability health outcomes people DHF .</brief_summary>
	<brief_title>Evaluating Effectiveness Sildenafil Improving Health Outcomes Exercise Ability People With Diastolic Heart Failure ( The RELAX Study )</brief_title>
	<detailed_description>DHF condition one chamber heart , leave ventricle , lose ability relax completely muscle become stiff . When occurs , heart unable properly fill blood , lead decrease blood circulation . People DHF may experience shortness breath pulmonary congestion , abnormal build-up fluid lung . Current treatment DHF include guidelines/recommendations low blood pressure , stop smoking , lose weight , medication available specifically treat DHF . Sildenafil , commonly know Revatio Viagra , medication increase supply blood lung reduces workload heart . Preliminary study show sildenafil may beneficial improve heart lung function people DHF , research need confirm finding . The purpose study determine sildenafil improve exercise ability health outcomes people DHF . This 24-week study enroll people DHF . Participants randomly assign receive either sildenafil placebo three time day 24 week . Participants attend study visit baseline Weeks 1 , 4 , 12 , 13 , 24 . At study visit , follow procedure occur : physical exam , medical history review , questionnaire , blood collection , 6-minute walk test measure endurance , exercise test . At baseline Week 24 , participant also undergo electrocardiogram , measure electrical activity heart , cardiac magnetic resonance imaging ( MRI ) procedure echocardiogram , obtain picture heart . At Weeks 3 , 8 , 16 , 20 , study researcher call participant collect health information .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Previous clinical diagnosis heart failure current New York Heart Association ( NYHA ) Class IIIV symptom Has experience least one follow 12 month study entry : Hospitalization decompensated heart failure Acute treatment intravenous loop diuretic hemofiltration Mean pulmonary capillary wedge pressure great 15 mm Hg leave ventricular end diastolic pressure ( LVEDP ) great 18 mm Hg catheterization dyspnea Long term treatment loop diuretic chronic diastolic dysfunction echocardiography , determine leave atrial enlargement Left ventricular ejection fraction great equal 50 % , determine clinical echocardiogram ventriculogram 12 month study entry Receiving stable medical therapy 30 day study entry , determine addition removal angiotensin convert enzyme inhibitor ( ACE ) , angiotensin receptor blocker ( ARB ) , betablockers , calcium channel blocker ( CCB ) change dosage ACE , ARBs , betablockers , CCBs 100 % Has neuromuscular , orthopedic , noncardiac condition prevents individual exercise test bicycle ergometer walk hallway Noncardiac condition limit life expectancy le 1 year time study entry , base judgment physician Current anticipate future need nitrate therapy Valve disease ( i.e. , great mild aortic mitral stenosis ; great moderate aortic mitral regurgitation ) Hypertrophic cardiomyopathy Infiltrative inflammatory myocardial disease ( e.g. , amyloid , sarcoid ) Pericardial disease Primary pulmonary arteriopathy Has experience heart attack unstable angina , undergone percutaneous transluminal coronary angiography ( PTCA ) coronary artery bypass grafting ( CABG ) 60 day study entry , require either PTCA CABG time study entry Other clinically important cause dyspnea , morbid obesity significant lung disease , define clinical judgment use steroid oxygen lung disease Systolic blood pressure le 110 mm Hg great 180 mm Hg Diastolic blood pressure le 40 mm Hg great 100 mm Hg Resting heart rate ( HR ) great 100 bpm History reduce ejection fraction ( le 50 % ) Implanted metallic device interfere MRI examination ( people without atrial fibrillation ) Severe kidney dysfunction ( estimate glomerular filtration rate [ GFR ] le 20 ml/min/1.73m2 modify modification diet renal disease [ MDRD ] equation ) Pregnant use effective form contraception Hemoglobin level le 10 g/dL Taking alpha antagonists cytochrome P450 3A4 inhibitor ( e.g. , ketoconazole , itraconazole , erythromycin , saquinavir , cimetidine , serum protease inhibitor HIV ) Retinitis pigmentosa , previous diagnosis nonischemic optic neuropathy , untreated proliferative retinopathy , unexplained visual disturbance Sickle cell anemia , multiple myeloma , leukemia , penile deformity increase risk priapism ( e.g. , angulation , cavernosal fibrosis , Peyronie 's disease ) Severe liver disease ( aspartate aminotransferase [ AST ] level great three time normal limit , alkaline phosphatase bilirubin great two time normal limit ) In consistent American College Cardiology ( ACC ) /American Heart Association ( AHA ) guideline , people dyspnea risk factor coronary artery disease stress test people clinically indicate stress test demonstrating significant ischemia 1 year study entry exclude . Listed heart transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Heart Failure , Diastolic</keyword>
	<keyword>Decompensated Heart Failure</keyword>
	<keyword>Sildenafil</keyword>
	<keyword>Exercise Capacity</keyword>
</DOC>